Exploiting conformational changes in a caffeine aptamer to engineer synthetic RNA devices
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkag584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Leon Kraus und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Caffeine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Biotechnology and Biological Sciences Research Council, Royal Academy of Engineering.
Abstract (Originalsprache)
RNA devices, including riboswitches, aptazymes, and RNA-based biosensors, have become essential components in synthetic and molecular biology. These systems make use of RNA’s modularity and structural diversity to build programmable tools for sensing, regulation, and cellular computation. To drive these systems, RNA aptamers usually need to undergo a conformational change upon ligand binding. However, the limited availability of such aptamers has restricted the development and application of RNA devices, particularly in mammalian systems. Traditional selection methods often prioritize high-affinity binding, resulting in a scarcity of conformation-switching aptamers. Here, we addressed this limitation by selecting a caffeine-binding aptamer with RNA Capture-SELEX and in vivo screenings. This aptamer functioned as a modular regulator of riboswitches and ribozymes in Saccharomyces cerevisiae and mammalian cells. Through new optofluidic screenings, we overcame throughput and sequence-function challenges inherent in ribozyme screening for mammalia. Additionally, a straightforward grafting method transformed the aptamer into a fluorogenic iSpinach aptasensor. This work demonstrates the successful selection of a modular and communicating aptamer for a challenging target like caffeine and establishes robust strategies for their modular integration into diverse RNA platforms. These strategies pave the way for broadening the repertoire of aptamers and expanding the potential of RNA-based synthetic biology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.
- Edinburgh Genome Foundry, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom.
- Mission Hub for Engineered Genetic Control Systems for Advanced Therapeutics, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom.
- UK Centre for Engineering Biology at the Institute of Quantitative Biology, Biochemistry, and Biotechnology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FF, United Kingdom.
- Centre for Synthetic Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.
ORCID-Profile: Leon Kraus, Robin Johannson, Sarah Hallstein, Susan J Rosser, Beatrix Suess
Förderung
- Deutsche Forschungsgemeinschaft
- Biotechnology and Biological Sciences Research Council
- Royal Academy of Engineering
Zitieren
APA
Kraus, L., Gunawan, V. J., Johannson, R., Hallstein, S., Block, S., Campbell, G. A., Alameen, A., Rosser, S. J., Mol, A. A., & Suess, B. (2026). Exploiting conformational changes in a caffeine aptamer to engineer synthetic RNA devices. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag584
Vancouver
Kraus L, Gunawan VJ, Johannson R, Hallstein S, Block S, Campbell GA, et al. Exploiting conformational changes in a caffeine aptamer to engineer synthetic RNA devices. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag584
BibTeX
@article{Kraus2026,
author = {Kraus, Leon and Gunawan, Vincent J and Johannson, Robin and Hallstein, Sarah and Block, Sina and Campbell, Gaynor A and Alameen, Alya and Rosser, Susan J and Mol, Adam A and Suess, Beatrix},
title = {Exploiting conformational changes in a caffeine aptamer to engineer synthetic RNA devices},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkag584}
}
EUVIMED